To include your compound in the COVID-19 Resource Center, submit it here.

BioBlast Pharma musculoskeletal news

BioBlast is reducing headcount by 8 (40%) to 12 and will focus development on 90 mg/mL IV trehalose

Read the full 187 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE